UNASSIGNED: The pregnancy hormone relaxin protects tissue from @entity2806 . The ability of @entity28758 , a relaxin paralog, to do so has not been explored. The cerebral expression levels of these peptides and their receptors make them logical targets for study in the @entity63 brain. We assessed relaxin peptide-mediated protection, relative relaxin family peptide receptor (RXFP) involvement, and protective mechanisms. @entity35 receiving permanent (pMCAO) or transient @entity2500 (tMCAO) were treated with relaxin peptides, and brains were collected for @entity1188 analysis. Activation of the endothelial nitric oxide synthase pathway was evaluated as a potential protective mechanism. Primary cortical @entity35 astrocytes were exposed to oxygen glucose deprivation and treated with relaxin peptides, and viability was examined. Receptor involvement was explored using @entity28759 antagonist or agonist treatment and real-time PCR. Relaxin and @entity28758 reduced @entity1188 size after pMCAO. Both peptides activated endothelial nitric oxide synthase. Because @entity28758 has not previously been associated with this pathway and displays promiscuous RXFP binding, we explored the receptor contribution. Expression of @entity21414 was greater than that of @entity28759 in @entity35 brain, although peptide binding at either receptor resulted in similar overall protection after pMCAO. Only @entity28759 activation reduced @entity1188 size after tMCAO. In astrocytes, @entity28759 gene expression was greater than that of @entity21414 . Selective activation of @entity28759 maintained astrocyte viability after oxygen glucose deprivation. Relaxin peptides are protective during the early stages of @entity385 . Differential responses among treatments and models suggest that @entity21414 and @entity28759 initiate different protective mechanisms. This preliminary work is a pivotal first step in identifying the clinical implications of relaxin peptides in @entity385 .

Relaxin Peptide Hormones Are Protective During the Early Stages of XXXX in Male @entity35 .

@entity28758 :: ('266997(Tax:10116)', 'Gene') :: ['relaxin-3'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['ischemic damage'] @entity2500 :: ('MESH:D020244', 'Disease') :: ['middle cerebral artery occlusions'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity21414 :: ('295144(Tax:10116)', 'Gene') :: ['RXFP1', 'rxfp1'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct'] @entity35 :: ('10116', 'Species') :: ['rat', 'Sprague-Dawley rats'] @entity28759 :: ('294807(Tax:10116)', 'Gene') :: ['RXFP3', 'rxfp3'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity385 :: (MESH:D002544,Disease) :: ['Ischemic Stroke']
